Drug intelligence / Profile preview

NP-50301

Development stage: Discontinued
Lead developer: Nascent Pharmaceuticals
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

NP-50301 is a small molecule ophthalmic therapeutic developed as a topical eye drop formulation of an estrogen ester compound. Its primary mechanism of action is as an agonist of estrogen receptor. The drug was developed for the treatment of post-menopausal Dry Eye Syndrome (DES) and xerophthalmia. Development was led by Nascent Pharmaceuticals and Xiamen Nanxun Co., Ltd. Clinical development reached up to Phase 2 trials but has since been discontinued[1][2][3].

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on NP-50301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-50301.

Explore the full profile